Clinical Use of Recombinant Human Erythropoietin in VLBW and ELBW Infants: a National Survey in China
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 500
- 主要终点
- The survey (the clinical use of rhEPO)
研究概览
简要总结
Recombinant human erythropoietin (rhEPO) has been shown to effectively and safely prevent the anemia of prematurity and to reduce the transfusion need in very low birth weight (VLBW) and extremly low birth weight (ELBW) infants and has been licensed for this indication in Europe in 1997. The objective of the study was to obtain information on the use or nonuse of rhEPO in neonatal units in China.
详细描述
The survey was developed by a team of neonatologists at Shenzhen People's hospital . The survey consisted of 26 questions covering three areas: the characteristics of the survey respondents, the use of rhEPO in VLBW and ELBW infants , and other related questions. The questionnaire was presented in the Questionnaire Star format (https://www.wjx.cn/, Hangzhou Oway Medical Technology,Changsha, China). we plan to conduct a cross-sectional survey through the Neonatal Professional Committee of the Chinese Medical Doctor Association WeChat platform. The questionnaire is going to be distributed to nearly 500 representative neonatologists and pediatricians from general hospitals, maternity and infant hospitals, and children's hospitals across the country. Furthermore, this study was approved by the ethics committee of the Shenzhen People's Hospital.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Cross Sectional
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •neonatologists and pediatricians from general hospitals, maternity and infant hospitals, and children's hospitals across China
排除标准
- •neonatologists and pediatricians from same hospitals
结局指标
主要结局
The survey (the clinical use of rhEPO)
时间窗: 01-june-2022
the clinical use of rhEPO in VLBW and ELBW infants
次要结局
未报告次要终点